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Abstract
Introduction: We investigate the risks of subsequent primary bone cancers after childhood and adolescent cancer in 12
European countries. For the first time, we satisfactorily address the risks beyond 40 years from diagnosis and beyond 40 years
of age among all survivors.
Methods: This largest-ever assembled cohort comprises 69 460 five-year survivors of cancer diagnosed before age 20 years.
Standardized incidence ratios, absolute excess risks, and multivariable-adjusted relative risks and relative excess risks were
calculated. All statistical tests were two-sided.
Results: Overall, survivors were 21.65 times (95% confidence interval¼ 18.97 to 24.60 times) more likely to be diagnosed with a
subsequent primary bone cancer than expected from the general population. The greatest excess numbers of bone cancers were
observed after retinoblastoma, bone sarcoma, and soft tissue sarcoma. The excess number of bone cancers declined linearly with both
years since diagnosis and attained age (all P< .05). Beyond 40years from diagnosis and age 40 years, there were at most 0.45 excess
bone cancers among all survivors per 10000 person-years at risk; beyond 30years from diagnosis and age 30 years, there were at most
5.02 excess bone cancers after each of retinoblastoma, bone sarcoma, and soft tissue sarcoma, per 10000 person-years at risk.
Conclusions: For all survivors combined and the cancer groups with the greatest excess number of bone cancers, the excess
numbers observed declined with both age and years from diagnosis. These results provide novel, reliable, and unbiased
information about risks and risk factors among long-term survivors of childhood and adolescent cancer.
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Article
Survival after childhood and adolescent cancer has improved
substantially, with approximately 80% of those diagnosed sur-
viving at least five years (1). As a result, there are now an esti-
mated 300 000 to 500 000 survivors of childhood and adolescent
cancer in Europe (2). However, increased survival comes at a
cost because the treatments utilized to achieve such successful
survival rates are also associated with adverse health outcomes.
One of the most serious such outcomes concerns subsequent
primary neoplasms (SPNs), with reports on cancer-related or
treatment-induced SPNs first being published in the 1970s (3).
Since then, numerous studies have demonstrated that there are
substantially higher risks of SPNs among the overall population
of childhood and adolescent cancer survivors compared with
that expected from the general population (4–9), with risks rang-
ing from three- to sixfold that expected (4–12). In particular,
when assessed by the SPN site, several reports have indicated
that, of all SPNs, subsequent primary bone cancers have the
greatest multiplicative excess risk (5,6), ranging from 10-fold to
45-fold that expected (4–6,8,13,14). However, the previous litera-
ture has generally been limited by a small number of bone
SPNs, and apart from European cohorts based on patients diag-
nosed before 1970 in France (14), the Nordic countries (4), and
the United Kingdom (5), the interval of follow-up from diagnosis
has been limited in other previous studies.
Thus, we sought to understand the risks of bone SPNs, both
overall and for specific morphological subtypes, using the
PanCare Childhood and Adolescent Cancer Survivor Care and
Follow-Up Studies (PanCareSurFup), the largest cohort of child-
hood and adolescent cancer survivors currently available. With
nearly 70 000 five-year survivors of cancer diagnosed before the
age of 20 and 235 observed bone SPNs, the latter being 2.5 times
more than in the largest previous report (5), the PanCareSurFup
SPN cohort gives an unrivaled opportunity to assess the long-
term risks of bone SPNs. In particular, our aims for this study
were to determine the risks and risk factors for bone SPNs in
this Europe-wide cohort and, in particular, to assess the risks
among survivors followed beyond 40 years from diagnosis or to
attained ages beyond 40 years.
Methods
PanCare Childhood and Adolescent Cancer Survivor
Care and Follow-Up Studies
PanCareSurFup (15) is a pan-European project within the larger
PanCare initiative (16) that seeks to better understand the fre-
quency, severity, and impact of late effects of childhood and ad-
olescent cancer. For this study, 13 population-based and
hospital-based cohorts of childhood and adolescent cancer sur-
vivors from the following 12 European countries were pooled to
assess the risk of bone SPNs: Denmark, Finland, France,
Hungary, Iceland, Italy, the Netherlands, Norway, Slovenia,
Sweden, Switzerland, and the United Kingdom. Ethical approval
was obtained separately within each participating country, ob-
serving all relevant national laws and requirements. The larger
European cohorts relating to specific countries included here
have been described in detail in a separate publication, together
with an overview of PanCareSurFup (17).
Cohort Ascertainment
All childhood and adolescent diagnoses within each of the 13
participating cohorts were pooled (n ¼ 105 015). In order to
classify the first primary neoplasms (FPNs) of each survivor
according to the International Classification of Childhood
Tumors (ICCC), third edition (18), all first primary neoplasms
(FPNs) were coded using the third revision of the International
Classification of Disease Oncology (ICD-O) with the aid of the
International Agency for Research on Cancer (IARC)/
International Association of Cancer Registries Check and
Conversion Program (19). As only typography data were avail-
able for Slovenian diagnoses before 1983, these survivors could
not be classified according to the ICCC (typography and mor-
phology required); these individuals were not excluded from
the study, but rather grouped into a “not classifiable” FPN type.
All remaining diagnoses that did not conform to the ICCC were
excluded. Furthermore, FPN diagnoses that did not have a ma-
lignant behavior were excluded, except for intracranial tumors
where benign and unspecified behaviors were included. To en-
sure consistency between cohorts, survivors diagnosed with
Langerhans cell histiocytosis, myelodysplastic syndromes,
chronic myeloproliferative, lymphoproliferative disorders, or
immunoproliferative diseases were excluded. Finally, only
those surviving at least five years after an initial diagnosis be-
fore age 20 years were included. Ultimately, 69 460 five-year sur-
vivors of childhood and adolescent cancer, diagnosed between
1940 and 2008, were included in this study (Supplementary
Figure 1, available online).
Subsequent Primary Neoplasm Ascertainment
The ascertainment method for SPNs varied by country
(Supplementary Table 1, available online), but the following
sources were utilized: population-based cancer registries, late
effect clinics, questionnaires, medical records and hospital
data, national mortality records, and health insurance regis-
tries. Validation of all SPNs was undertaken principally using
pathology reports, although occasionally other definitive diag-
nostic reports were used. To be included, SPNs had to be histo-
logically different from the FPN and have a malignant behavior
code. For this study, all bone SPNs occurred in a bone site and
were classified according to the following morphological
groups: osteosarcoma, chondrosarcoma, Ewing sarcoma, and all
other bone SPNs (Supplementary Table 2, available online).
General Population Cancer Rates
General population cancer rates were obtained from the IARC’s
Cancer Incidence in Five Continents Time Trends (20). Country-
specific rates for bone cancer overall were available for all coun-
tries, except Hungary. Morphology-specific bone cancer rates
were available for all countries, except Hungary, Slovenia,
Sweden, Norway, and Finland. To estimate missing rates, we
utilized the Italian general population rates for Hungary and
Slovenia and Danish general population rates for Finland,
Norway, and Sweden; Italy and Denmark were selected due to
their relatively close geographical proximity to the correspond-
ing countries with missing general population data. If the range
of calendar years for the general population rates did not cover
the ascertainment period of the SPNs for a country, rates from
the closest available year were used.
Statistical Analyses
Follow-up for a bone SPN began five years after the FPN diagno-
sis date and ended at the first occurrence of loss to follow-up,
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death, or the study exit date (Supplementary Table 1, available
online). Standardized incidence ratios were calculated as the ob-
served divided by the expected number of bone cancers.
Absolute excess risks per 10 000 person-years were calculated as
the observed minus the expected number of bone cancers, di-
vided by person-years at risk and multiplied by 10 000. For both
the standardized incidence ratio and absolute excess risk calcu-
lations, multiple SPNs were included to avoid bias. We concen-
trate on absolute excess risks rather than standardized incidence
ratios because of their direct and clear interpretation as the ex-
cess numbers of SPNs beyond that expected per 10 000 person-
years. The expected number of bone cancers was calculated by
multiplying the person-years for each sex-, age (five-year)-, and
calendar year (one-year)–specific stratum by the corresponding
general population cancer rate and then summing across the
strata. Using multivariable Poisson regression models, we also
provide relative risks (RRs) and relative excess risks (RERs), which
can be interpreted as the ratios of standardized incidence ratios
and absolute excess risks, respectively, with respect to a speci-
fied reference category having adjusted for all other explanatory
factors included within the model. The following explanatory
factors were adjusted for within the models: sex, cohort, FPN di-
agnosis, age at diagnosis, treatment era, and years since diagno-
sis or attained age; years since diagnosis and attained age were
not included in the same model due to collinearity. Likelihood ra-
tio tests were utilized to test for heterogeneity and linear trends.
The cumulative probability of bone SPNs, in relation to years
since diagnosis, was calculated including the first bone SPN
only, where death was treated as a competing risk. All statistical
analyses were conducted using Stata 13.1 (21), where the crite-
rion for statistical significance was a two-sided P value of less
than .05.
Data Availability
The data are not publicly available due to them containing
semi-identifiable information that could compromise research
participant privacy. Nonetheless, additional summary tables of
count data or person-years are available from the correspond-
ing author upon request.
Results
Study Characteristics
Individuals in the cohort were followed-up for a total of 1 126
424 person-years. The median follow-up time from FPN diagno-
sis was 21.4 years (range ¼ 5.0–66.6 years), and the median
attained age was 29.7 years (range ¼ 5.0–79.4 years) at study
exit. Among the 69 460 cancer survivors included in the cohort,
235 bone SPNs were observed among 230 survivors (Table 1).
Bone SPNs were most frequently observed among survivors of
retinoblastoma (73 SPNs), bone sarcoma (37 SPNs), and soft tis-
sue sarcoma (STS) (37 SPNs), which when combined accounted
for nearly two-thirds of all bone SPNs observed.
Risks and Risk Factors of Bone SPNs Overall
Overall, survivors were 21.65 times (95% CI ¼ 18.97 to 24.60
times) more likely to experience a bone SPN than expected,
which equated to 1.99 (95% CI ¼ 1.72 to 2.26) excess bone can-
cers per 10 000 person-years (Tables 2). When the risk of a bone
SPN was assessed by FPN diagnosis, all diagnostic groups were
found to have at least a fivefold increased risk compared with
that expected (Table 3). Retinoblastoma survivors were found to
have the greatest excess risks both in multiplicative and abso-
lute terms, with a standardized incidence ratio of 134.91 (95% CI
¼ 105.74 to 169.62) and 12.03 (95% CI ¼ 9.25 to 14.81) excess bone
cancers per 10 000 person-years. Bone sarcoma and STS survi-
vors had the next greatest excess risks at 78.18-fold (95% CI ¼
55.04 to 107.75) and 46.77-fold (95% CI¼ 32.93 to 64.47) that
expected, respectively. After all FPNs combined, there was not a
statistically significant linear trend in excess risks (RRs or RERs)
of bone SPN with either age at diagnosis of FPN or treatment era
of FPN when adjusted, but as years since diagnosis and attained
age increased, both the relative risks and relative excess risks
statistically significantly declined (all Ptrend < .001). Specifically,
from the age range of five to 19 years to 40þ years of age, the
standardized incidence ratio declined from 28.98 (95% CI¼ 24.62
to 33.88) to 6.96 (95% CI¼ 2.55 to 15.14). Beyond 40 years from di-
agnosis and age 40 years, there were at most 0.45 excess bone
SPNs per 10 000 person-years. At 45 years since diagnosis, the
cumulative incidence of a bone SPN was 0.6% compared with
0.03% of the expected (Figure 1A).
Risks and Risk Factors of Bone SPNs by FPN
As retinoblastoma, bone sarcoma, and STS survivors experi-
enced the greatest risks of developing a bone SPN, these three
groups were explored in more detail. When explanatory factors
were assessed, male retinoblastoma survivors were found to
have a statistically significantly greater absolute excess risk
than female retinoblastoma survivors after adjustment for po-
tential confounders (Pheterogeneity ¼ .04) (Table 4); no statistically
significant effects were observed for the sex of bone sarcoma or
STS survivors. There was no evidence of a relationship between
excess risks (RRs or RERs) for bone SPNs and age at diagnosis, af-
ter adjustment, for bone sarcoma or STS survivors; age at diag-
nosis was not assessed as a risk factor for retinoblastoma
survivors as 95.3% of these survivors were diagnosed at zero to
four years. There was also no evidence of an increasing or de-
creasing linear trend in the excess risks (RRs or RERs) for bone
SPNs among survivors of retinoblastoma, bone sarcoma, or STS
treated in more recent eras. For retinoblastoma, bone sarcoma,
and STS survivors, as years since diagnosis and attained age in-
creased, the RERs declined linearly (all Ptrend < .05). Beyond
30 years from diagnosis and age 30 years, there were at most
5.02 excess bone cancers per 10 000 person-years among survi-
vors of each of retinoblastoma, bone sarcoma, and STS. In Table
4, we also provide the excess numbers of bone SPNs after all
FPNs except retinoblastoma, bone sarcoma, and STS. Overall,
0.85 (95% CI¼ 0.65 to 1.04) excess bone SPNs were experienced
per 10 000 person-years. This excess number declined (all Ptrend
< .05) linearly with increased years from diagnosis and attained
age. When the cumulative probability was assessed by FPN
type, the risk was greatest for retinoblastoma survivors, reach-
ing 3.2% at 25 years from diagnosis, while the corresponding cu-
mulative probabilities for bone sarcoma, STS, all other FPNs,
and that expected from the general population were 1.4%, 0.9%,
0.2%, and 0.02%, respectively (Figure 1B).
Risks and Risk Factors of Morphology-Specific Bone
SPNs
When assessed by morphological subtype, 179 osteosarcoma,
14 Ewing sarcoma, 21 chondrosarcoma, and 21 other bone SPNs
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were observed (Table 2); the corresponding standardized inci-
dence ratios were 41.37 (95% CI¼ 35.53 to 47.90), 5.71 (95%
CI¼ 3.12 to 9.58), 11.39 (95% CI¼ 7.05 to 17.41), and 9.37 (95%
CI¼ 5.80 to 14.32). At 30 years from the FPN diagnosis, the cumu-
lative probabilities for osteosarcoma, chondrosarcoma, and
other bone SPNs were approximately 70 times (0.3%), 40 times
(0.04%), and 50 times (0.05%) that expected for each respective
morphological subtype; the cumulative probability for Ewing
sarcoma SPNs at 20 years was 20 times (0.02%) that expected
(Figure 1C).
As 76.2% of the bone SPNs observed were osteosarcomas, poten-
tial explanatory factors were investigated only for this group (Table
3). Although both standardized incidence ratios and absolute excess
risks were generally numerically greater for osteosarcoma than for
bone SPNs overall, the pattern of relationships with explanatory
factors was very similar to those seen for bone SPNs overall.
Table 1. Participant characteristics overall and by whether they have a subsequent primary bone neoplasm*
Survivor characteristic No. of patients without a bone SPN (%) No. of patients with at least 1 bone SPN (%) Total No. (%)
Overall 69 230 (100.0) 230 (100.0) 69 460 (100.0)
Sex
Male 37 597 (54.3) 141 (61.3) 37 738 (54.3)
Female 31 633 (45.7) 89 (38.7) 31 722 (45.7)
Cohort
United Kingdom 17 869 (25.8) 91 (39.6) 17 960 (25.9)
France 3098 (4.5) 40 (17.4) 3138 (4.5)
Hungary 4875 (7.0) 10 (4.3) 4885 (7.0)
Italy (population-based) 7466 (10.8) 10 (4.3) 7476 (10.8)
Italy (hospital-based) 1484 (2.1) 6 (2.6) 1490 (2.1)
Netherlands 6025 (8.7) 19 (8.3) 6044 (8.7)
Denmark 4831 (7.0) 9 (3.9) 4840 (7.0)
Sweden 7700 (11.1) 9 (3.9) 7709 (11.1)
Norway 3776 (5.5) 7 (3.0) 3783 (5.4)
Finland 6216 (9.0) 13 (5.7) 6229 (9.0)
Iceland 274 (0.4) 1 (0.4) 275 (0.4)
Slovenia 1250 (1.8) 2 (0.9) 1252 (1.8)
Switzerland 4366 (6.3) 13 (5.7) 4379 (6.3)
Age at diagnosis, y
0–4 26 832 (38.8) 136 (59.1) 26 968 (38.8)
5–9 15 542 (22.4) 45 (19.6) 15 587 (22.4)
10–14 15 384 (22.2) 39 (17.0) 15 423 (22.2)
15–19 11 472 (16.6) 10 (4.3) 11 482 (16.5)
First primary neoplasm diagnosis
Leukemia 16 582 (24.0) 13 (5.7) 16 595 (23.9)
Hodgkin disease 5984 (8.6) 16 (7.0) 6000 (8.6)
Non-Hodgkin lymphoma 3345 (4.8) 5 (2.2) 3350 (4.8)
Central nervous system tumors 14 084 (20.3) 12 (5.2) 14 096 (20.3)
Neuroblastoma 3163 (4.6) 6 (2.6) 3169 (4.6)
Retinoblastoma 2505 (3.6) 73 (31.7) 2578 (3.7)
Wilms 4742 (6.8) 14 (6.1) 4756 (6.8)
Bone sarcoma 3111 (4.5) 36 (15.7) 3147 (4.5)
Soft tissue sarcoma 4466 (6.5) 35 (15.2) 4501 (6.5)
Other 10 887 (15.7) 18 (7.8) 10 905 (15.7)
Not classifiable 361 (0.5) 2 (0.9) 363 (0.5)
Treatment era
1940–1969 8944 (12.9) 49 (21.3) 8993 (12.9)
1970–1979 13 395 (19.3) 84 (36.5) 13 479 (19.4)
1980–1989 20 843 (30.1) 57 (24.8) 20 900 (30.1)
1990–1999 19 226 (27.8) 34 (14.8) 19 260 (27.7)
2000þ 6822 (9.9) 6 (2.6) 6828 (9.8)
Years since diagnosis
5–9 13 367 (19.3) 75 (32.6) 13 442 (19.4)
10–19 23 056 (33.3) 114 (49.6) 23 170 (33.4)
20–29 17 683 (25.5) 32 (13.9) 17 715 (25.5)
30–39 10 033 (14.5) 7 (3.0) 10 040 (14.5)
40þ 5091 (7.4) 2 (0.9) 5093 (7.3)
Attained age, y
5–19 16 279 (23.5) 152 (66.1) 16 431 (23.7)
20–29 22 593 (32.6) 47 (20.4) 22 640 (32.6)
30–39 17 404 (25.1) 25 (10.9) 17 429 (25.1)
40þ 12 954 (18.7) 6 (2.6) 12 960 (18.7)
*SPN ¼ subsequent primary neoplasm.
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Discussion
Our study is the largest ever to assess the risk of bone SPNs
among childhood and adolescent cancer survivors, with 69 460
five-year survivors, 1 126 424 person-years at risk, and 235 ob-
served bone SPNs. There were more than 100 000 and 30 000
person-years accrued among survivors beyond age 40 years and
beyond 40 years from diagnosis, respectively, enabling satisfac-
tory assessment of excess risks for these groups of survivors for
the first time. Among all five-year survivors, as years from diag-
nosis and attained age increased, both multiplicative and abso-
lute excess risks declined linearly; among those surviving
beyond 40 years from diagnosis and beyond 40 years of age, the
excess number of bone cancers did not exceed 0.5 per 10 000
persons per year. After each of retinoblastoma, bone sarcoma,
and STS, the excess number of bone cancers also declined line-
arly with both increased years from diagnosis and increased
attained age; beyond 30 years from diagnosis and age 30 years,
there were at most five excess bone cancers observed per 10 000
person-years for each FPN type. Finally, there was no evidence
of a relationship between excess risks (RRs or RERs) for bone
SPNs and either age at diagnosis or treatment era, after taking
into account confounding.
Overall, the risk of a bone SPN was 22 times that expected
from the general population, which is consistent with previous
studies (4–6,8,13). The risk of a bone SPN was observed to vary
by morphological subtype, with the multiplicative excess risks
ranging from six times that expected from the general popula-
tion for Ewing sarcoma SPNs to 41 times that expected from the
general population for osteosarcoma SPNs.
Survivors of retinoblastoma, bone sarcoma, and STS were
observed to have the greatest risks of a bone SPNs, with risks of
135, 78, and 47 times that expected, respectively; these results
are consistent with previous reports (6,13,22–30). The large in-
creased risk observed in retinoblastoma survivors likely corre-
sponds to the fact that heritable retinoblastoma survivors
develop bone SPNs, particularly osteosarcomas, at substantially
greater frequencies than the general population due to a genetic
predisposition (13,28,30), in addition to the increased risk result-
ing from radiotherapy and chemotherapy experienced by both
heritable and nonheritable survivors. For bone sarcoma and STS
survivors, exposure to radiation and chemotherapy, specifically
alkylating agents, has been previously shown to increase the
risk of bone SPNs (13,22,26,28). Previous reports have also found
increased risks of bone SPNs among bone sarcoma and STS sur-
vivors independent of treatment, which suggests potential ge-
netic predisposition as well (6,28).
Previous studies have suggested that bone SPNs after child-
hood and adolescent cancer largely occur in the short term fol-
lowing the original cancer, but these reports were based on
limited follow-up (10,22). Our findings indicate for the first time
that the excess number of bone cancers decline with both years
from diagnosis and attained age to beyond 40 years in each
timescale. It is important to remember, however, that the cur-
rent survivors living beyond 40 years from diagnosis or attaining
ages beyond 40 years may not be representative of future survi-
vors reaching these milestones. Therefore, the presented find-
ings are only applicable to survivors who have at least 40 years
since diagnosis or 40 years’ attained age at the time of the study,
which largely comprises survivors of central nervous system
neoplasms, Hodgkin lymphoma, retinoblastoma, and Wilms
tumors. It will be important to reassess our findings with addi-
tional follow-up in order to determine whether the risks of bone
SPNs remain low among more recently treated survivors reach-
ing mature adulthood.
Finally, the excess number of bone cancers observed did not
vary with more recent treatment era after all cancers, retino-
blastoma, bone sarcoma, or STS, whereas five-year survival has
improved substantially over the recent treatment eras covered
by our data. For example, in Britain, five-year survival after all
childhood cancers diagnosed in 1966–1970 and 1996–2000 in-
creased from 28% to 77%; corresponding figures after retinoblas-
toma, bone sarcoma, and STS were 86% to 96%, 23% to 64%, and
32% to 66%, respectively (31). As treatment intensity generally
increased in order to achieve such substantial improvements in
five-year survival over the treatment eras covered by our data,
it is very reassuring that the excess numbers of bone SPNs have
not increased following treatment from 1940–1969 to beyond
2000.
A potential limitation of our study is the statistically signifi-
cant heterogeneity in bone SPN risks between cohorts. The
most likely explanation of this heterogeneity relates to different
cumulative levels of exposure to radiation (from radiotherapy)
and cytotoxic drugs carcinogenic to bone between countries,
resulting from differences in treatment practices over time (32).
Although we were not able to find evidence of this in the litera-
ture for the at-risk groups identified in this study, variations in
British, German, and Nordic treatment regimens were clearly
documented for acute myeloid leukemia patients (33–35), and
thus our explanation seems plausible. As detailed treatment in-
formation was unavailable in this study, we were not able to in-
vestigate further this hypothesis within our data, nor calculate
dose-response relationships between the risk of development
of bone SPNs and cumulative doses of radiotherapy and chemo-
therapy. Also, information on cancer-predisposing genetic con-
ditions was lacking, and therefore it was not possible to stratify
results by, for example, heritability status for retinoblastoma
survivors. However, as we are undertaking nested case-control
studies as a part of PanCareSurFup, we shall overcome each of
these limitations in the future, particularly in regards to
whether there is evidence of variation in dose responses be-
tween cohorts.
Table 2. Standardized incidence ratios and absolute excess risks for bone subsequent primary neoplasms overall and by morphological
subtype*
Type of subsequent primary neoplasm O/E SIR (95% CI) AER (95% CI)
All bone 235/10.9 21.65 (18.97 to 24.60) 1.99 (1.72 to 2.26)
Osteosarcoma 179/4.3 41.37 (35.54 to 47.90) 1.55 (1.32 to 1.78)
Ewing sarcoma 14/2.5 5.71 (3.12 to 9.58) 0.10 (0.04 to 0.17)
Chondrosarcoma 21/1.8 11.39 (7.05 to 17.41) 0.17 (0.09 to 0.25)
Other bone 21/2.2 9.37 (5.80 to 14.32) 0.17 (0.09 to 0.25)
*AER ¼ absolute excess risk; CI ¼ confidence interval; E ¼ expected; O ¼ observed; SIR ¼ standardized incidence ratio.
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Figure 1. Cumulative probability curves for bone subsequent primary neoplasms (SPNs), by time since diagnosis. A) The observed cumulative probability for a bone
SPN, with the corresponding 95% confidence intervals (dashed lines), compared with the expected cumulative probability from the general population. B) The cumula-
tive probability for a bone SPN for survivors of retinoblastoma, bone sarcoma, soft tissue sarcoma, and all other first primary neoplasm types compared with that
expected from the general population. C) The cumulative probability for an osteosarcoma SPN, chondrosarcoma SPN, Ewing sarcoma SPN, and all other bone SPNs
compared with that expected from the general population.
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This largest-ever investigation into the risk of bone SPNs af-
ter childhood and adolescent cancers has provided strong evi-
dence that the excess number of bone SPNs observed after all
childhood cancer, retinoblastoma, bone sarcomas, and STS
declines linearly with both increased years since diagnosis and
attained age. Beyond 40 years from diagnosis and age 40 years,
there were at most 0.45 excess bone SPNs among all survivors
per 10 000 person-years at risk; beyond 30 years from diagnosis
and age 30 years, there were at most 5.02 excess bone SPNs after
each of retinoblastoma, bone sarcoma, and STS per 10 000
person-years at risk. Despite the substantial improvement in
five-year survival after each of these cancer groups since 1940
and the associated more intensive treatment, the excess num-
ber of bone SPNs observed has not increased among survivors
of more recent treatments. The evidence assembled in this
study provides reliable and unbiased information about risks
and risk factors among long-term survivors not previously
available, which is likely to be helpful to both survivors and
health care professionals.
Funding
This work was supported by the European Union’s Seventh
Framework Programme for research, technological develop-
ment and demonstration, under grant agreement number
257505. Additional financial support was received from The
Italian Association for Cancer Research, Compagnia San Paolo,
The Fondo Chiara Rama OLUS, The Swedish Childhood Cancer
Foundation, The Norwegian Childhood Cancer Foundation, La
Ligue Nationale Contre le Cancer, Agence Nationale pour la
Recherche Scientifique, Institut National du Cancer, Fondation
Pfizer pour la sante´ de l’enfant et de l’adolescent, Slovenian
Research Agency, The Swiss Paediatric Oncology Group, The
Swiss Cancer League, The Swiss Cancer Research Foundation,
The Swiss National Science Foundation, The Dutch Cancer
Society, and the European Union’s Seventh Framework
Programme Marie Curie Actions – People – COFUND.
Notes
Authors: Miranda M. Fidler, Raoul C. Reulen, David L. Winter,
Rodrigue S. Allodji, Francesca Bagnasco, Edit Bardi, Andrea
Bautz, Chloe J. Bright, Julianne Byrne, Elizabeth A. M. Feijen,
Stanislaw Garwicz, Desiree Grabow, Thorgerdur
Gudmundsdottir, Joyeeta Guha, Nadia Haddy, Momcilo
Jankovic, Peter Kaatsch, Melanie Kaiser, Rahel Kuonen, Helena
Linge, Milena Maule, Franco Merletti, Hilde Øfstaas, Cecile M.
Ronckers, Roderick Skinner, Jop Teepen, Monica Terenziani,
Giao Vu-Bezin, Finn Wesenberg, Thomas Wiebe, Zsuzsanna
Jakab, Riccardo Haupt, P€aivi L€ahteenm€aki, Lorna Zadravec
Zaletel, Claudia E. Kuehni, Jeanette F. Winther, Florent de
Vathaire, Leontien C. Kremer, Lars Hjorth, Michael M. Hawkins
Affiliations of authors: Centre for Childhood Cancer Survivor
Studies, Institute of Applied Health Research, University of
Birmingham, Birmingham, UK (MMF, RCR, DLW, CJB, JG, MMH);
Section of Cancer Surveillance, International Agency for
Research on Cancer, Lyon, France (MMF); Cancer and Radiation
Team, U1018 INSERM, Villejuif, France (RSA, NH, GVB, FdV);
Epidemiology and Biostatistics Section, Gaslini Children
Hospital, Genova, Italy (FB, RH); 2nd Department of Pediatrics,
Semmelweis University, Budapest, Hungary (EB); Kepler
Universit€atsklinikum, Linz, Austria (EB); Survivorship Unit,
Danish Cancer Society Research Center, Copenhagen, Denmark
(AB, TG, JFW); Boyne Research Institute, Drogheda, Ireland (JB);
Department of Pediatric Oncology, Emma Children’s Hospital/
Academic Medical Center, Amsterdam, the Netherlands (EAMF,
CMR, JT, LCK); Department of Pediatrics, Skane University
Hospital, Lund University, Lund, Sweden (SG, HL, TW, LH);
German Childhood Cancer Registry, Institute of Medical
Biostatistics, Epidemiology and Informatics, University Medical
Center, Mainz, Germany (DG, PK, MK); Children’s Hospital,
Landspitali University Hospital, Reykjavik, Iceland (TG);
Pediatric Hematology Unit, San Gerardo Hospital, Monza, Italy
(MJ); Swiss Childhood Cancer Registry, Institute of Social and
Preventive Medicine, University of Bern, Bern, Switzerland (RK,
CEK); Childhood Cancer Registry of Piedmont, Cancer
Epidemiology Unit, Department of Medical Sciences, University
of Turin and AOU Citta della Salute e della Scienza di Torino,
Torino, Italy (MM, FM); Norwegian National Advisory Unit on
Solid Tumors in Children (HØ); Great North Children’s Hospital,
Newcastle upon Tyne Hospitals NHS Foundation Trust, and
Northern Institute of Cancer Research, Newcastle University,
Newcastle upon Tyne, UK (RS); Pediatric Oncology Unit,
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
(MT); Norwegian Cancer Registry and Department of Pediatric
Medicine, Oslo University Hospital, Oslo, Norway (FW); Faculty
of Medicine, Institute of Clinical Medicine, University of Oslo,
Norway (FW); Hungarian Childhood Cancer Registry, 2nd
Department of Pediatrics, Semmelweis University, Budapest,
Hungary (ZJ); Department of Pediatrics and Adolescent
Medicine, Turku University and Turku University Hospital,
Turku, Finland (PL); Institute of Oncology, Ljubljana, Slovenia
(LZZ); Department of Pediatrics, University Children’s Hospital
of Bern, University of Bern, Bern, Switzerland (CEK).
The funders had no role in design of the study; the collec-
tion, analysis, or interpretation of the data; the writing of the
manuscript; or the decision to submit the manuscript for publi-
cation. The lead and corresponding authors had full access to
all the data in the study and had final responsibility for the deci-
sion to submit for publication.
We are very grateful to the childhood and adolescent cancer
survivors whose information was used for PanCareSurFup. We
also would like to thank the following individuals from each coun-
try: France: Angela Jackson, Florent Dayet, Amar Kahlouche, Fara
Diop, Sylvie Challeton, Martine Labbe´, Isao Kobayashi; Italy: Maura
Massimino, Silvia Caruso, Monica Muraca, Vera Morsellino,
Claudia Casella, Lucia Miligi, Anita Andreano, AIRTUM working
group; Slovenia: Tina Zagar; Sweden: Ingemar Andersson,
Susanne Nordenfelt; Switzerland: Eva Hau-Grosch, Elisabeth
Kiraly, Gisela Michel, Vera Mitter, Shelagh Redmond, the Swiss
Paediatric Oncology Group; Denmark: Andrea Bautz, Childhood
Cancer Survivorship Research Group, Danish Cancer Society
Research Center; UK: Julie Kelly; the Netherlands: Dutch
Childhood Oncology Group LATER, Wim Tissing, Flora van
Leeuwen, Marry van den Heuvel-Eibrink, Eline van Dulmen,
Jacqueline Loonen, Dorine Bresters, Birgitta Versluys.
The views expressed in this publication are those of the
authors and do not necessarily represent those of the funders
or the individuals listed in the acknowledgements.
References
1. Gatta G, Botta L, Rossi S, et al. Childhood cancer survival in Europe 1999-2007:
Results of EUROCARE-5—a population-based study. Lancet Oncol. 2014;15(1):
35–47.
2. European Commission. Improving healthcare for young cancer survivors.
http://ec.europa.eu/programmes/horizon2020/en/news/improving-healthcare-
young-cancer-survivors. Accessed January 9, 2017.
A
R
T
IC
LE
M. M. Fidler et al. | 11 of 12
3. Li FP, Cassady JR, Jaffe N. Risk of second tumors in survivors of childhood
cancer. Cancer. 1975;35(4):1230–1235.
4. Olsen JH, Mo¨ller T, Anderson H, et al. Lifelong cancer incidence in 47,697
patients treated for childhood cancer in the Nordic countries. J Natl Cancer
Inst. 2009;101(11):806–813.
5. Reulen RC, Frobisher C, Winter DL, et al. Long-term risks of subsequent pri-
mary neoplasms among survivors of childhood cancer. JAMA. 2011;305(22):
2311–2319.
6. Neglia JP, Friedman DL, Yasui Y, et al. Second malignant neoplasms in five-
year survivors of childhood cancer: Childhood cancer survivor study. J Natl
Cancer Inst. 2001;93(8):618–629.
7. Magnani C, Terracini B, Cordero Di Montezemolo L, et al. Incidence of second
primary malignancies after a malignant tumor in childhood: A population-
based survey in Piedmont (Italy). Int J Cancer. 1996;67(1):6–10.
8. Cardous-Ubbink MC, Heinen RC, Bakker PJM, et al. Risk of second malignan-
cies in long-term survivors of childhood cancer. Eur J Cancer. 2007;43(2):
351–362.
9. Inskip PD, Curtis RE. New malignancies following childhood cancer in the
United States, 1973-2002. Int J Cancer. 2007;121(10):2233–2240.
10. Friedman DL, Whitton J, Leisenring W, et al. Subsequent neoplasms in 5-year
survivors of childhood cancer: The Childhood Cancer Survivor Study. J Natl
Cancer Inst. 2010;102(14):1083–1095.
11. Jenkinson HC, Hawkins MM, Stiller CA, Winter DL, Marsden HB, Stevens
MCG. Long-term population-based risks of second malignant neoplasms af-
ter childhood cancer in Britain. Br J Cancer. 2004;91(11):1905–1910.
12. Wilson CL, Cohn RJ, Johnston KA, Ashton LJ. Late mortality and second can-
cers in an Australian cohort of childhood cancer survivors. Med J Aust. 2010;
193(5):258–261.
13. Hawkins MM, Kinnier Wilson LM, Burton HS, et al. Radiotherapy, alkylating
agents, and risk of bone cancer after childhood cancer. J Natl Cancer Inst. 1996;
88(5):270–278.
14. Schwartz B, Benadjaoud MA, Cle´ro E, et al. Risk of second bone sarcoma fol-
lowing childhood cancer: Role of radiation therapy treatment. Radiat Environ
Biophys. 2014;53(2):381–390.
15. PanCareSurFup. http://www.pancaresurfup.eu/. Accessed December 6, 2015.
16. Hjorth L, Haupt R, Skinner R, et al. Survivorship after childhood cancer:
PanCare: A European Network to promote optimal long-term care. Eur J
Cancer. 2015;51(10):1203–1211.
17. Winther JF, Kenborg L, Byrne J, et al. Childhood cancer survivor cohorts in
Europe. Acta Oncol (Madr). 2015;54(5):655–668.
18. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International
Classification of Childhood Cancer, third edition. Cancer. 2005;103(7):
1457–1467.
19. International Association of Cancer Registries. Check and
conversion program. http://www.iacr.com.fr/index.php?option¼com_
content&view¼article&id¼72:iarccrgtools&catid¼68&Itemid¼445. Accessed
December 6, 2015.
20. International Agency for Research on Cancer. CI5plus: Cancer incidence in
five continents time trends. 2016. http://ci5.iarc.fr/CI5plus/Default.aspx.
Accessed January 9, 2017.
21. StatCorp. Stata Statistical Software: Release 13. 2013. http://www.stata.com/.
Accessed December 6, 2015.
22. Henderson TO, Whitton J, Stovall M, et al. Secondary sarcomas in childhood
cancer survivors: A report from the Childhood Cancer Survivor Study. J Natl
Cancer Inst. 2007;99(4):300–308.
23. Fidler MMM, Frobisher C, Guha J, et al. Long-term adverse outcomes in survi-
vors of childhood bone sarcoma: The British Childhood Cancer Survivor
Study. Br J Cancer. 2015;112(12):1857–1865.
24. Moll AC, Imhof SM, Bouter LM, Tan KE. Second primary tumors in patients with
retinoblastoma. A review of the literature.Ophthalmic Genet. 1997;18(1):27–34.
25. Woo KI, Harbour JW. Review of 676 second primary tumors in patients with
retinoblastoma: Association between age at onset and tumor type. Arch
Ophthalmol (Chicago, Ill 1960). 2010;128(7):865–870.
26. Tucker MA, D’Angio GJ, Boice JD, et al. Bone sarcomas linked to radiotherapy
and chemotherapy in children. N Engl J Med. 1987;317(10):588–593.
27. Newton WA, Meadows AT, Shimada H, Bunin GR, Vawter GF. Bone sarcomas
as second malignant neoplasms following childhood cancer. Cancer. 1991;
67(1):193–201.
28. Le Vu B, de Vathaire F, Shamsaldin A, et al. Radiation dose, chemotherapy
and risk of osteosarcoma after solid tumours during childhood. Int J Cancer.
1998;77(3):370–377.
29. Garwicz S, Anderson H, Olsen JH, et al. Second malignant neoplasms after
cancer in childhood and adolescence: A population-based case-control study
in the 5 Nordic countries. The Nordic Society for Pediatric Hematology and
Oncology. The Association of the Nordic Cancer Registries. Int J Cancer. 2000;
88(4):672–678.
30. Hansen MF, Koufos A, Gallie BL, et al. Osteosarcoma and retinoblastoma: A
shared chromosomal mechanism revealing recessive predisposition. Proc
Natl Acad Sci U S A. 1985;82(18):6216–6220.
31. Stiller C. Childhood Cancer in Britain. Oxford: Oxford University Press; 2007.
32. Turcotte LM, Liu Q, Yasui Y, et al. Temporal trends in treatment and subse-
quent neoplasm risk among 5-year survivors of childhood cancer, 1970-2015.
JAMA. 2017;317(8):814.
33. Creutzig U, Ritter J, Zimmermann M, et al. Improved treatment results in
high-risk pediatric acute myeloid leukemia patients after intensification
with high-dose cytarabine and mitoxantrone: Results of Study Acute Myeloid
Leukemia–Berlin-Frankfurt-Mu¨nster 93. J Clin Oncol. 2001;19(10):2705–2713.
34. Stevens RF, Hann IM, Wheatley K, Gray RG. Marked improvements in out-
come with chemotherapy alone in paediatric acute myeloid leukemia:
Results of the United Kingdom Medical Research Council’s 10th AML trial.
MRC Childhood Leukaemia Working Party. Br J Haematol. 1998;101(1):130–140.
35. Lie SO, Abrahamsson J, Clausen N, et al. Long-term results in children with
AML: NOPHO-AML Study Group–report of three consecutive trials. Leukemia.
2005;19(12):2090–2100.
A
R
T
IC
LE
12 of 12 | JNCI J Natl Cancer Inst, 2018, Vol. 110, No. 2
